Antigen heterogeneity, such as varying levels of HER2 expression in breast cancer, can result in suboptimal binding and reduced drug delivery, while changes in antigen expression during disease progression further diminish ADC efficacy (Schettini and Prat, 2021; Li et al., 2024). Here, ERBB2 is linked to breast cancer.